Astrana Health, Inc. announced its consolidated financial results for the second quarter ended June 30, 2025. The company reported total revenue of $654.808 million, representing a 35% increase compared to $486.265 million in Q2 2024. Adjusted EBITDA for the quarter was $47.5 million, up 10% from $43.2 million in the prior year's second quarter.
Net income attributable to Astrana Health, Inc. for Q2 2025 was $9.423 million, a decrease from $19.171 million in Q2 2024. President and CEO Brandon Sim highlighted robust revenue expansion and strong operational execution, noting that 78% of revenue now comes from full-risk models, an increase from 60% a year ago.
The company reiterated its full-year 2025 guidance, projecting total revenue between $3.1 billion and $3.3 billion and Adjusted EBITDA between $215 million and $225 million. This reaffirmed guidance reflects the positive impact of the recently closed Prospect Health acquisition and continued momentum in value-based care arrangements.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.